Synthetic Biologics Stock Quote SYN - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.02

Bid

Ask

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

17.384M

Previous Close

1.02

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

17,043,000

Dividend Yield

PE Ratio

-3.53

Earnings Per Share (EPS)

-1.08

Revenue

Net Profit

-18.35M

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbio... Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Show more

Sector

Pharmaceutical Preparations

Industry

Business Services

Website

www.syntheticbiologics.com

Headquarters

Rockville, Maryland, USA

Founded

1993

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference PR Newswire ROCKVILLE, Md., Feb. 9, 2022 ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE...

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA Follows recent announcement of planned acquisition of VCN Biosciences...

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022 PR Newswire ROCKVILLE, Md., Jan. 26, 2022 ROCKVILLE, Md., Jan. 26, 2022 /PRNewswire/ -- Synthetic...

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors Lead drug candidate...

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Initiated a Phase 1 Multiple Ascending Dose Clinical...

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021 -- Conference Call Scheduled for Wednesday, November 3, 2021 at 4:30 p.m. ET...

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase Topline Data Readout Expected in Q2 2022 Phase 1 Clinical...

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum The Company Encourages All Shareholders of Record Who Have Not Yet Voted to Do So by...

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum PR Newswire ROCKVILLE, Md., Sept. 21, 2021 ROCKVILLE, Md., Sept. 21, 2021 /PRNewswire/...

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Phase 1 Single-Ascending Dose Clinical Trial of...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
EONREON Resources Inc	$ 1.28 (29.29%)	1
GNSGenius Group Limited	$ 0.85 (10.15%)	2
ETHU2x Ether ETF	$ 5.98 (7.65%)	75.3k
ETHTProshares Ultra Ether ETF	$ 15.54 (7.47%)	3.72k
SCPXScorpius Holdings Inc	$ 0.8647 (7.14%)	5
NBYNovaBay Pharmaceuticals Inc New	$ 0.645 (-12.84%)	92.43k
PZGParamount Gold and Silver Corp	$ 0.445 (-12.75%)	123
AIMAIM ImmunoTech Inc	$ 0.2395 (-10.37%)	132
ETHDProshares Ultrashort Ether ETF	$ 55.72 (-7.35%)	7
RCGRENN Fund Inc	$ 1.92 (-6.80%)	1
SOXLDirexion Daily Semiconductor Bull 3X Shares	$ 33.42 (-0.39%)	792.21k
SOXSDirexion Daily Semiconductor Bear 3X Shares New	$ 22.83 (0.57%)	407.57k
SPXSDirexion Daily S&P 500 Bear 3X Shares New	$ 6.91 (0.00%)	300.1k
SPXUProShares UltraPro Short S&P 500	$ 25.33 (0.00%)	237.35k
SSOProShares Ultra S&P 500	$ 88.70 (0.08%)	167.74k